164 related articles for article (PubMed ID: 38337419)
1. Antibodies against Small Ubiquitin-like Modifier Activating Enzyme May Be a Protective Factor from Rapid Progressive Interstitial Lung Disease in Patients Bearing Antibodies against Melanoma Differentiation Associated Gene 5.
Tsai HC; Chen WS; Sun YS; Lai CC; Yang YY; Chou WR; Liao HT; Tsai CY; Chou CT
J Clin Med; 2024 Jan; 13(3):. PubMed ID: 38337419
[No Abstract] [Full Text] [Related]
2. Roles of biomarkers in anti-MDA5-positive dermatomyositis, associated interstitial lung disease, and rapidly progressive interstitial lung disease.
Li X; Liu Y; Cheng L; Huang Y; Yan S; Li H; Zhan H; Li Y
J Clin Lab Anal; 2022 Nov; 36(11):e24726. PubMed ID: 36221983
[TBL] [Abstract][Full Text] [Related]
3. IL-15 is a biomarker involved in the development of rapidly progressive interstitial lung disease complicated with polymyositis/dermatomyositis.
Shimizu T; Koga T; Furukawa K; Horai Y; Fujikawa K; Okada A; Okamoto M; Endo Y; Tsuji S; Takatani A; Umeda M; Fukui S; Sumiyoshi R; Kawashiri SY; Iwamoto N; Igawa T; Ichinose K; Tamai M; Sakamoto N; Nakamura H; Origuchi T; Mukae H; Kuwana M; Kawakami A
J Intern Med; 2021 Feb; 289(2):206-220. PubMed ID: 32691471
[TBL] [Abstract][Full Text] [Related]
4. WDFY4 polymorphisms in Chinese patients with anti-MDA5 dermatomyositis is associated with rapid progressive interstitial lung disease.
Guo L; Zhang X; Pu W; Zhao J; Wang K; Zhang D; Hong S; Ma Y; Wang X; Ye S; Guo Q; Wang J
Rheumatology (Oxford); 2023 Jun; 62(6):2320-2324. PubMed ID: 36637178
[TBL] [Abstract][Full Text] [Related]
5. Assessment of anti-MDA5 antibody as a diagnostic biomarker in patients with dermatomyositis-associated interstitial lung disease or rapidly progressive interstitial lung disease.
Li L; Wang Q; Wen X; Liu C; Wu C; Yang F; Zeng X; Li Y
Oncotarget; 2017 Sep; 8(44):76129-76140. PubMed ID: 29100298
[TBL] [Abstract][Full Text] [Related]
6. [Risk Factors of Rapidly Progressive Interstitial Lung Disease in Patients With Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis].
Han YY; Jiang T; Zhang ZH; Li W; Jiang YD; Lu CC; Fei Y; Chen B
Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 54(2):422-425. PubMed ID: 36949709
[TBL] [Abstract][Full Text] [Related]
7. Identification of Three Different Phenotypes in Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis Patients: Implications for Prediction of Rapidly Progressive Interstitial Lung Disease.
Xu L; You H; Wang L; Lv C; Yuan F; Li J; Wu M; Da Z; Wei H; Yan W; Zhou L; Yin S; Zhou D; Wu J; Lu Y; Su D; Liu Z; Liu L; Ma L; Xu X; Zang Y; Liu H; Ren T; Wang F; Du Y; Xue J; Zhang M; Tan W
Arthritis Rheumatol; 2023 Apr; 75(4):609-619. PubMed ID: 35849805
[TBL] [Abstract][Full Text] [Related]
8. Time-dependent changes in RPILD and mortality risk in anti-MDA5+ DM patients: a cohort study of 272 cases in China.
You H; Wang L; Wang J; Lv C; Xu L; Yuan F; Li J; Wu M; Zhou S; Da Z; Qian J; Wei H; Yan W; Zhou L; Wang Y; Yin S; Zhou D; Wu J; Lu Y; Su D; Liu Z; Liu L; Ma L; Xu X; Zang Y; Liu H; Ren T; Wang F; Zhang M; Tan W
Rheumatology (Oxford); 2023 Mar; 62(3):1216-1226. PubMed ID: 35961045
[TBL] [Abstract][Full Text] [Related]
9. Gender differences in patients with anti-MDA5-positive dermatomyositis: a cohort study of 251 cases.
Cheng L; Xu L; Xu Y; Yuan F; Li J; Wu M; Da Z; Wei H; Zhou L; Yin S; Wu J; Lu Y; Su D; Liu Z; Liu L; Ma L; Xu X; Liu H; Ren T; Zang Y
Clin Rheumatol; 2024 Jan; 43(1):339-347. PubMed ID: 37985533
[TBL] [Abstract][Full Text] [Related]
10. Clinical features and immune-related protein patterns of anti-MDA5 positive clinically amyopathic dermatomyositis Dutch patients.
Hensgens MPM; Delemarre EM; Drylewicz J; Voortman M; Krol RM; Dalm VASH; Miedema JR; Wiertz I; Grutters J; Limper M; Nierkens S; Leavis HL
Rheumatology (Oxford); 2022 Oct; 61(10):4087-4096. PubMed ID: 35048953
[TBL] [Abstract][Full Text] [Related]
11. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM.
Koga T; Fujikawa K; Horai Y; Okada A; Kawashiri SY; Iwamoto N; Suzuki T; Nakashima Y; Tamai M; Arima K; Yamasaki S; Nakamura H; Origuchi T; Hamaguchi Y; Fujimoto M; Ishimatsu Y; Mukae H; Kuwana M; Kohno S; Eguchi K; Aoyagi K; Kawakami A
Rheumatology (Oxford); 2012 Jul; 51(7):1278-84. PubMed ID: 22378718
[TBL] [Abstract][Full Text] [Related]
12. Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody.
Jiang L; Wang Y; Peng Q; Shu X; Wang G; Wu X
Clin Rheumatol; 2019 Jun; 38(6):1655-1663. PubMed ID: 30739212
[TBL] [Abstract][Full Text] [Related]
13. α2,3-Sialylation with Fucosylation Associated with More Severe Anti-MDA5 Positive Dermatomyositis Induced by Rapidly Progressive Interstitial Lung Disease.
Zhang R; Guo L; Sha J; Chang S; Zhao J; Wang K; Wang J; Gu J; Liu J; Ren S
Phenomics; 2023 Oct; 3(5):457-468. PubMed ID: 37881316
[TBL] [Abstract][Full Text] [Related]
14. Serum IgA levels for predicting the development of rapidly progressive interstitial lung disease in dermatomyositis.
Zhang H; Liang R; Yuan X; Zheng Z; Lai W
Respir Med; 2023 Sep; 216():107322. PubMed ID: 37302423
[TBL] [Abstract][Full Text] [Related]
15. Different Multivariable Risk Factors for Rapid Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis and Anti-Synthetase Syndrome.
Zuo Y; Ye L; Chen F; Shen Y; Lu X; Wang G; Shu X
Front Immunol; 2022; 13():845988. PubMed ID: 35320936
[TBL] [Abstract][Full Text] [Related]
16. Clinical Utility of an Enzyme-Linked Immunosorbent Assay for Detecting Anti-Melanoma Differentiation-Associated Gene 5 Autoantibodies.
Sato S; Murakami A; Kuwajima A; Takehara K; Mimori T; Kawakami A; Mishima M; Suda T; Seishima M; Fujimoto M; Kuwana M
PLoS One; 2016; 11(4):e0154285. PubMed ID: 27115353
[TBL] [Abstract][Full Text] [Related]
17. Hypouricemia as a novel predictor of mortality in anti-MDA5 positive dermatomyositis patients with ILD: A retrospective cohort study.
Liu H; Chen B; Guo Y; Liu H; Ran J; Liu R; Yin G; Xie Q
Respir Med; 2024 Feb; 222():107530. PubMed ID: 38228214
[TBL] [Abstract][Full Text] [Related]
18. Interstitial Lung Disease in Dermatomyositis Without Myositis-Specific and Myositis-Associated Autoantibodies: Study of a Series of 72 Patients From a Single Cohort.
Chen F; Wang J; Zhang P; Zuo Y; Ye L; Wang G; Shu X
Front Immunol; 2022; 13():879266. PubMed ID: 35603153
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: A case report.
Endo Y; Koga T; Suzuki T; Hara K; Ishida M; Fujita Y; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Umeda M; Fukui S; Nishino A; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Kuwana M; Kawakami A
Medicine (Baltimore); 2018 Apr; 97(15):e0436. PubMed ID: 29642214
[TBL] [Abstract][Full Text] [Related]
20. Soluble CXCL16 is a prognostic biomarker associated with rapidly progressive interstitial lung disease complicated with dermatomyositis.
Li C; Han Y; Li X; Zhang H; Yao Z; Zhou J; Mu R; Zhao J
Semin Arthritis Rheum; 2024 Aug; 67():152483. PubMed ID: 38843569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
